Literature DB >> 1820305

Anorexia in the terminally ill cancer patient: the emotional impact on the patient and the family.

C M Holden.   

Abstract

Anorexia is a troublesome symptom, experienced by the majority of cancer patients. Loss of appetite in the terminally ill patient is seen as a certain sign of impending death and is a source of considerable anxiety. This study was designed to explore the ways in which terminally ill cancer patients and their primary caregivers view and respond to the patient's loss of appetite. Semi-structured interviews were conducted to elicit data. Findings suggest that loss of appetite is indeed a source of anxiety and conflict within the family, and that the amount of food and fluid taken is used as a barometer of the patient's overall condition. Findings also suggest that caregiver anxiety is more pronounced in the female than in the male because the patient's inability to eat impacts upon her customary role identity. The majority of patients viewed anorexia to be of less concern than other problems, and also voiced a preference to have their family members focus less energy on encouraging them to eat.

Entities:  

Mesh:

Year:  1991        PMID: 1820305     DOI: 10.1080/0742-969x.1991.11882706

Source DB:  PubMed          Journal:  Hosp J        ISSN: 0742-969X


  10 in total

Review 1.  Palliative medicine.

Authors:  R J George; A L Jennings
Journal:  Postgrad Med J       Date:  1993-06       Impact factor: 2.401

2.  Clinical management of dying patients.

Authors:  J Gavrin; C R Chapman
Journal:  West J Med       Date:  1995-09

3.  Coping with newly diagnosed upper gastrointestinal cancer: a longitudinal qualitative study of family caregivers' role perception and supportive care needs.

Authors:  Joanne Shaw; James Harrison; Jane Young; Phyllis Butow; Charbel Sandroussi; David Martin; Michael Solomon
Journal:  Support Care Cancer       Date:  2012-08-30       Impact factor: 3.603

4.  An explorative study of the views and experiences of food and weight loss in patients with operable pancreatic cancer perioperatively and following surgical intervention.

Authors:  C Cooper; S T Burden; Alex Molassiotis
Journal:  Support Care Cancer       Date:  2014-10-03       Impact factor: 3.603

Review 5.  A systematic review of health-related quality of life instruments in patients with cancer cachexia.

Authors:  Sally Wheelwright; Anne-Sophie Darlington; Jane B Hopkinson; Deborah Fitzsimmons; Alice White; Colin D Johnson
Journal:  Support Care Cancer       Date:  2013-06-25       Impact factor: 3.603

6.  Understanding and managing cancer-related weight loss and anorexia: insights from a systematic review of qualitative research.

Authors:  Christine Cooper; Sorrel T Burden; Huilin Cheng; Alex Molassiotis
Journal:  J Cachexia Sarcopenia Muscle       Date:  2015-03-31       Impact factor: 12.910

7.  Eating-related distress and need for nutritional support of families of advanced cancer patients: a nationwide survey of bereaved family members.

Authors:  Koji Amano; Isseki Maeda; Tatsuya Morita; Yoshiro Okajima; Takashi Hama; Maho Aoyama; Yoshiyuki Kizawa; Satoru Tsuneto; Yasuo Shima; Mitsunori Miyashita
Journal:  J Cachexia Sarcopenia Muscle       Date:  2016-02-15       Impact factor: 12.910

8.  Health care professionals' experience, understanding and perception of need of advanced cancer patients with cachexia and their families: The benefits of a dedicated clinic.

Authors:  David Scott; Joanne Reid; Peter Hudson; Peter Martin; Sam Porter
Journal:  BMC Palliat Care       Date:  2016-12-30       Impact factor: 3.234

Review 9.  A Systematic Review and Meta-Analysis of the Clinical Use of Megestrol Acetate for Cancer-Related Anorexia/Cachexia.

Authors:  Yu Liang Lim; Seth En Teoh; Clyve Yu Leon Yaow; Daryl Jimian Lin; Yoshio Masuda; Ming Xuan Han; Wee Song Yeo; Qin Xiang Ng
Journal:  J Clin Med       Date:  2022-06-28       Impact factor: 4.964

10.  Psychosocial impact of cancer cachexia.

Authors:  Jane B Hopkinson
Journal:  J Cachexia Sarcopenia Muscle       Date:  2014-04-16       Impact factor: 12.910

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.